tag:blogger.com,1999:blog-8066238290370557389.post6435970774944978133..comments2024-03-20T04:44:15.540-05:00Comments on Controversies in Hospital Infection Prevention: A change of heart on vancomycin MICs?Dan Diekemahttp://www.blogger.com/profile/10231929371552334184noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-8066238290370557389.post-17200190108639956522012-01-24T07:30:50.857-06:002012-01-24T07:30:50.857-06:00I agree with everything you said Dan. I would add...I agree with everything you said Dan. I would add that there were only 118 patients with few (composite) outcomes to base their analyses on. They even called it a case-control study incorrectly when it is actually a matched cohort study and I could go on. Calling Don Goldmann, Don??<br /><br />Since this is a subscription-based publication (not open-access), you can't easily see the conflicts of interest for the authors of the related editorial. I have pasted them in quotes to help you out.<br /><br />"H. W. B. serves or has served as an adviser/consultant to Basilea, Cerexa, Durata, J&J, Merck (adjudication committee), Rib-X, Wyeth/Pfizer (DSMB), and Targanta/TMC in the past 2 years. She previously served as a consultant for Cubist."Eli Perencevichhttps://www.blogger.com/profile/05131155100606411030noreply@blogger.com